Anika Therapeutics

Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Anika Therapeutics reports strong Q4 earnings, eyes growth opportunities

Anika Therapeutics delivered strong financial performance in Q4 2022, with revenue growth and strategic investments driving growth targets for 2023. The company is focused on product launches, expanding its portfolio, and preparing for the launch of the RevoMotion Reverse Shoulder System.
While facing challenges such as higher stock-based compensation and lower EBITDA expected in 2023, Anika remains optimistic about the value inflection point in 2023. The company's emphasis on growth initiatives and commercial optimization positions it for future opportunities.

Anika Therapeutics reports growth in core segments and strategic investments

Anika Therapeutics showed positive revenue growth in Q1, driven by core business segments.
Despite a net loss, Anika is strategically positioning itself as a global leader in joint preservation.
Investments in new products and regulatory progress with Cingal indicate a focus on innovation and expansion.
Maintaining strong gross margins amidst increased operating expenses highlights operational efficiency.

Anika Therapeutics posts robust Q2 results, eyes growth opportunities

Anika Therapeutics reported strong Q2 results, raising its revenue outlook for 2023.
Despite international challenges, the company sees opportunities for growth in key segments.
Progress in FDA approvals, partnerships, and new product launches position Anika for future success.
Maintaining a focus on innovation and market expansion will be crucial for sustained growth.

Anika Therapeutics raises guidance on strong Q3 performance and outlook

Anika Therapeutics showcased robust growth in key segments, leading to an optimistic outlook for the year. Despite challenges in restructuring sales operations, the company is well-positioned for continued success with a focus on profitability and new product launches.

Anika Therapeutics exceeds Q4 expectations, eyes Hyalofast's U.S. potential

Anika Therapeutics delivered robust financial performance, focusing on driving new products for growth and operational efficiency. The company aims to accelerate profitability targets and is on track with product launches, making strategic adjustments based on feedback.

Anika Therapeutics reports Q1 revenue growth and strategic product advancements

Anika Therapeutics demonstrated solid financial performance in Q1 2024, driven by revenue growth, cost reduction initiatives, and positive market feedback on key products.
While facing challenges such as FDA approval requirements and leadership transition, the company's strengths in product portfolio and distribution agreements position it well for future growth.
Opportunities in FDA designations, revenue growth expectations, and operational improvements present avenues for Anika to enhance market presence and financial performance in the coming quarters.

Anika Therapeutics reports Q3 revenue, focuses on core products

Anika Therapeutics faces challenges with workforce reduction and financial losses
However, strategic focus on core HA products and revenue reclassification show promise
Opportunities lie in revenue growth in the commercial channel and long-term investments
Overall, Anika Therapeutics aims for sustainable growth and value creation

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company's main focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and its products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika Therapeutics was founded in 1992 and is headquartered in Bedford, MA.

Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Anika Therapeutics (ANIK) Q2 Earnings Expected to Decline

Innovative Products Designed to Meet Needs of Surgeons and their Patients in Joint Preservation and Restoration Procedures  Innovative Products Designed to Meet Needs of Surgeons and their Patients in Joint Preservation and Restoration Procedures

Anika To Launch Six FDA-Cleared Sports Medicine and Extremities Products in Third Quarter of 2020

BEDFORD, Mass., July  16, 2020  (GLOBE NEWSWIRE) --  Anika Therapeutics, Inc.  (NASDAQ: ANIK), a global, integrated joint preservation, restoration and regenerative solutions company with products across the orthopedic early intervention continuum of care, today announced that the Company plans to issue its second quarter 2020 financial results after the close of the market on Thursday, July 30, 2020 and hold its investor conference call on the same day, Thursday, July 30, 2020, at 5:00 p.m. ET to discuss its financial results, business highlights, and outlook.

Anika to Issue Second Quarter 2020 Financial Results and Business Highlights on Thursday, July 30

Sylvia Cheung to Step Down in August 2020

Anika Announces Planned CFO Transition

Anika Therapeutics, Inc.'s (ANIK) CEO Cheryl Blanchard on Q1 2020 Results - Earnings Call Transcript

Anika (ANIK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Anika (ANIK) Moves to Buy: Rationale Behind the Upgrade

Anika Therapeutics (ANIK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

BEDFORD, Mass., April  08, 2020  (GLOBE NEWSWIRE) --  Anika Therapeutics, Inc.  (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (“HA”) technology platform, today provided an update on actions it is taking to strengthen liquidity in light of the COVID-19 pandemic.

Anika Takes Actions to Strengthen Liquidity in Light of COVID-19

A recent acquisition and a new product launch held back earnings, but should be beneficial over the long term.

Anika Therapeutics Beats Revenue and Earnings Estimates

Anika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q4 2019 Results - Earnings Call Transcript

Anika (ANIK) delivered earnings and revenue surprises of 4.88% and 7.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Anika Therapeutics (ANIK) Beats Q4 Earnings and Revenue Estimates

BEDFORD, Mass., Feb.  12, 2020  (GLOBE NEWSWIRE) --  Anika Therapeutics, Inc.  (NASDAQ: ANIK) today announced that Dr. Cheryl Blanchard, a member of the Company’s Board of Directors since August 2018, has been named interim Chief Executive Officer, effective immediately, while the Board continues its search to identify a new CEO following the recent passing of Joseph Darling. In connection with Dr. Blanchard’s appointment, the previously announced interim Office of the President has been dissolved.

Anika Therapeutics Names Board Member Dr. Cheryl Blanchard as Interim CEO

Transaction Accelerates Anika’s Revenue Growth, Broadens Joint Preservation and Restoration Product Portfolio, Enhances Commercial Capabilities and Expands Pipeline Transaction Accelerates Anika’s Revenue Growth, Broadens Joint Preservation and Restoration Product Portfolio, Enhances Commercial Capabilities and Expands Pipeline

Anika Therapeutics Closes Acquisition of Arthrosurface

BEDFORD, Mass., Jan.  29, 2020  (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK) announced today with great sadness that Joseph Darling, its President and Chief Executive Officer, passed away unexpectedly on January 29, 2020 in Upstate New York. He was 62.

Anika Therapeutics Mourns the Sudden Passing of Joseph Darling, President and Chief Executive Officer

Anika Therapeutics Closes Acquisition of Parcus Medical

ACADIA Pharma

Alexion Pharma

Gilead Sciences

Incyte

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Biotech Stock Outlook: M&A Activity Retains Growth Streak

BioDelivery Sciences

Crocs

Plexus

Unifi

Possibility of at least an interim trade deal between the largest trading countries of the world  boosted investors' confidence on risky assets like equities.

5 Top Momentum Stocks in October That Still Have Upside Left

Does Anika Therapeutics (ANIK) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Anika Therapeutics (ANIK) a Strong Momentum Stock: Buy Now?

As of late, it has definitely been a great time to be an investor in Anika Therapeutics, Inc. (ANIK).

Anika Therapeutics, Inc. (ANIK) Shares March Higher, Can It Continue?

Anika Therapeutics Inc. (ANIK) CEO Joseph Darling on Q3 2019 Results - Earnings Call Transcript

Anika (ANIK) delivered earnings and revenue surprises of 56.10% and 9.61%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Anika Therapeutics (ANIK) Q3 Earnings and Revenues Surpass Estimates

KB Home

NetEase

Taylor Morrison Home

Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

5 Stocks With Recent Price Strength Despite Trade Jitters

Is  (ANIK) Outperforming Other Medical Stocks This Year?

Has Anika Therapeutics (ANIK) Outpaced Other Medical Stocks This Year?

Anika (ANIK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

News for Anika Therapeutics Stock (ANIK)